Ablynx is a Belgian biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments. The Company has proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease.
Type
Public
HQ
Gent, BE
Founded
2001
Size (employees)
344 (est)
Website
ablynx.com
Ablynx was founded in 2001 and is headquartered in Gent, BE

Key People/Management at Ablynx

Frank Landolt

Frank Landolt

IP and legal counsel
Guido Gielen

Guido Gielen

VP Human Resources

Ablynx Office Locations

Ablynx has an office in Gent
Gent, BE (HQ)
21 Technologiepark-Zwijnaarde

Ablynx Financials and Metrics

Ablynx Financials

EUR

Market capitalization (16-Nov-2016)

584.9 b

Closing share price (16-Nov-2016)

9.6
Ablynx's current market capitalization is €584.9 b.
Show all financial metrics

Ablynx Market Value History

Ablynx's Web-traffic and Trends

Ablynx Online and Social Media Presence

Ablynx News and Updates

VC-backed Albynx debuts U.S. IPO

Ablynx, a Belgian biopharmaceutical company, has raised $200 million for its U.S. IPO after pricing its 11.4 million shares at $17.50 per share. The stock began trading October 25, 2017 on the NASDAQ under the ticker symbol “ABLX.” BofA Merrill Lynch, J.P. Morgan and Jefferies are the lead underwrit…

VC-backed Ablynx files for IPO

Ablynx, a Belgian biopharmaceutical company, has filed for an IPO. The number of shares that will be sold as well as the stock's pricing terms have yet to be set. Ablynx, which currently trades on the Euronext Brussels, is planning on listing its U.S. stock on the NASDAQ under the ticker symbol ABLX…

Ablynx Company Life and Culture

You may also be interested in